Neuroendocrinology News

Individuals with adult-onset craniopharyngioma reported postoperative quality of life measures that were comparable with those of other primary and secondary brain tumors, despite the benign biology of the condition, according to an analysis of German registry data published in The Journal of Clinical Endocrinology & Metabolism.

Hypogonadism occurs in more than half of men using opioids, and hypocortisolism occurs in approximately one-fifth of all patients, according to findings from a meta-analysis of more than 50 studies.

The steroidogenesis inhibitor levoketoconazole was effective in reducing and normalizing morning urinary free cortisol concentrations and biomarkers of cardiovascular risk among a large cohort of adults with endogenous Cushing’s syndrome, as well as improving clinical signs of the disease and quality of life measures, according to findings published in The Lancet Diabetes & Endocrinology.

For patients with persistent or recurring Cushing’s disease, monthly pasireotide therapy was safe and effective, leading to normal urinary free cortisol levels in 47% of patients after 2 years, according to findings published in Clinical Endocrinology.

Endocrine Today has compiled a list of the top 10 news reports posted so far in of 2019.

Each month Endocrine Today reporters delve deep into a topic of current interest. These longform cover stories provide background and insights from leading researchers and clinicians. All of these features can be found under the opinion tab above and at the links below. Stories published so far in 2019 include emerging alternatives in thyroid cancer treatment, promising developments in beta-cell regeneration, questions about vitamin D’s effectiveness, and more.

An estimated 40% to 50% of childhood cancer survivors will experience an endocrine disorder in their lifetime. The risk varies according to cancer treatment and can persist for decades after diagnosis.

Each month in its cover story, Endocrine Today offers comprehensive reporting on issues of interest to practicing endocrinologists, diabetes educators and other clinicians.

The off-label use of recombinant human growth hormone as an anti-aging “wonder drug” — despite evidence suggesting serious associated risks — continues to rise in the United States and worldwide, an issue that is confounding endocrinologists who note that lower levels of GH could actually be protective in aging.

Endocrine Today has compiled a list of the top five news reports with expert perspectives posted in May. Healio.com/Endocrinology readers were interested in a drop in diabetes incidence, an increase in pediatric DKA cases, benefits of bariatric surgery for teens, and more.